Comparative Pharmacology
Head-to-head clinical analysis: BRISTAGEN versus GENOPTIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRISTAGEN versus GENOPTIC.
BRISTAGEN vs GENOPTIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bristagen (amikacin) is an aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis.
Genoptic (gentamicin ophthalmic) is an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and production of nonfunctional proteins.
1-2 mg/kg IM or IV every 8-12 hours; typical adult dose is 1 mg/kg every 8 hours.
Instill 1-2 drops into affected eye(s) every 4-6 hours; for severe infections, every 1-2 hours initially, then reduce frequency as improvement occurs.
None Documented
None Documented
2.5 hours (prolonged to 20-40 hours in renal impairment).
2-3 hours (prolonged in renal impairment to 18-24 hours); in neonates, 3-8 hours.
Renal (90% unchanged via glomerular filtration); biliary/fecal excretion <10%.
Primarily renal (70-90% unchanged) via glomerular filtration and tubular secretion; biliary/fecal <5%.
Category C
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic